Related Experiment Video

Updated: Sep 20, 2025

Translational Rabbit Model of Chronic Cardiac Pacing
06:14

Translational Rabbit Model of Chronic Cardiac Pacing

Published on: January 6, 2023

2.7K

A leadless pacemaker matched with a vasovagal syncope: how long can it last?

Mohamed ElRefai1,2, Christina Menexi1, Mohamed Abouelasaad1

  • 1Cardiac Rhythm Management Research Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Pacing and Clinical Electrophysiology : PACE
|June 12, 2022
PubMed

Insights

Leadless pacemakers (LPs) show promising battery longevity in vasovagal syncope (VVS) patients, lasting over 15 years. This offers a viable alternative to traditional pacing for VVS, though longer-term data is still needed.

Area of Science:

  • Cardiology
  • Medical Devices
  • Electrophysiology

Background:

  • Cardiac pacing is recommended for frequent vasovagal syncope (VVS) episodes.
  • Leadless pacemakers (LPs) are a safe and effective alternative to transvenous pacing for VVS.
  • Concerns exist regarding LP battery longevity in younger patients requiring long-term therapy.

Purpose of the Study:

  • To evaluate the battery longevity of LPs in patients with VVS.
  • To compare LP battery performance in VVS patients versus those with other pacing indications.

Main Methods:

  • Retrospective analysis of 100 LPs implanted at a UK tertiary cardiac center.
  • Collected demographical and device data at implant and follow-up.
  • Compared LP battery life in VVS patients to patients with other pacing indications.

Main Results:

  • 14% of patients had VVS; 84% had other indications.
  • Mean age for VVS patients was 34 ± 13 years; for others, 62 ± 20 years.
  • Estimated battery life was 15.22 ± 0.35 years for VVS and 13.65 ± 2.97 years for other indications (p=0.04). No complications in the VVS group.

Conclusions:

  • LPs offer promising short/intermediate-term battery performance for VVS patients.
  • LPs are a viable pacing option for vasovagal syncope.
  • Longer-term follow-up is necessary to confirm true battery potential in this cohort.
Abstract

Keywords:
Leadless pacemakersSyncopebattery longevitypacing therapy

More Related Videos

A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts07:56

A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts

Published on: February 17, 2023

1.0K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Related Concept Videos

Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
128
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
750
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
115
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.1K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
34
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
86